Informatie:
Fout:
ID
34554
Beschrijving
An Observational Study on The Safety and Effectiveness of Mabthera (Rituximab) in The First Six Months of Treatment in Patients With Severe Active Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01071798
Link
https://clinicaltrials.gov/show/NCT01071798
Trefwoorden
Versies (1)
- 19-01-19 19-01-19 -
Houder van rechten
see on clinicaltrials.gov
Geüploaded op
19 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Rheumatoid Arthritis NCT01071798
Eligibility Rheumatoid Arthritis NCT01071798
- StudyEvent: Eligibility
Similar models
Eligibility Rheumatoid Arthritis NCT01071798
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
adult patients, >/= 18 years of age
boolean
ID.2
Item
severe active rheumatoid arthritis; eligible for treatment with rituximab according to current spc
boolean
ID.3
Item
informed consent to data collection
boolean
ID.4
Item
ongoing contraception (for female patients only)
boolean
ID.5
Item
previous treatment with rituximab (mabthera)
boolean
ID.6
Item
allergy against monoclonal antibodies, respectively chimeric monoclonal antibodies
boolean
ID.7
Item
active severe infection
boolean
ID.8
Item
severe heart failure (nyha class iv) or severe, uncontrolled cardiac disease
boolean
ID.9
Item
treatment in other studies within 3 months before rituximab therapy
boolean
ID.10
Item
pregnancy or breast feeding
boolean